# Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself

> **NCT00457678** · PHASE2 · WITHDRAWN · sponsor: **Vitreous -Retina- Macula Consultants of New York**

## Conditions studied

- Age Related Macular Degeneration

## Interventions

- **DRUG:** Visudyne
- **DRUG:** Lucentis
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT00457678
- **Lead sponsor:** Vitreous -Retina- Macula Consultants of New York
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-01
- **Primary completion:** 2007-12-04
- **Final completion:** 2007-12-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Site did not enroll any patients to the study.
- **Last updated:** 2017-08-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00457678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00457678, "Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00457678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*